- MeSH
- Hospitals history MeSH
- Hospital Departments history MeSH
- Nuclear Medicine Department, Hospital * history MeSH
- Publication type
- Historical Article MeSH
- Geographicals
- Czech Republic MeSH
- Publication type
- Meeting Abstract MeSH
- MeSH
- Albuminuria complications MeSH
- Renal Insufficiency, Chronic epidemiology etiology MeSH
- Diabetes Mellitus, Type 2 * complications blood MeSH
- Diabetic Retinopathy * epidemiology etiology MeSH
- Diabetic Angiopathies epidemiology MeSH
- Diabetic Nephropathies * epidemiology MeSH
- Glycated Hemoglobin * metabolism MeSH
- Clinical Trials as Topic MeSH
- Middle Aged MeSH
- Humans MeSH
- Multicenter Studies as Topic MeSH
- Observational Studies as Topic MeSH
- Prevalence MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Comment MeSH
- Overall MeSH
- Geographicals
- Italy MeSH
- MeSH
- Diabetes Mellitus, Type 2 * drug therapy MeSH
- Fibroblast Growth Factors metabolism secretion MeSH
- Sodium-Glucose Transporter 2 Inhibitors MeSH
- Glucagon-Like Peptide 1 analogs & derivatives administration & dosage pharmacokinetics physiology therapeutic use MeSH
- Glucokinase administration & dosage pharmacokinetics therapeutic use MeSH
- Glycated Hemoglobin secretion MeSH
- Drug Evaluation * MeSH
- Hydroxysteroid Dehydrogenases administration & dosage metabolism therapeutic use MeSH
- Hypoglycemic Agents * blood urine MeSH
- Dipeptidyl-Peptidase IV Inhibitors administration & dosage pharmacokinetics metabolism adverse effects therapeutic use MeSH
- Insulin analogs & derivatives administration & dosage pharmacokinetics therapeutic use MeSH
- Clinical Trials as Topic MeSH
- Drug Therapy, Combination MeSH
- Delayed-Action Preparations pharmacokinetics MeSH
- Humans MeSH
- Meta-Analysis as Topic MeSH
- Sodium-Glucose Transporter 1 antagonists & inhibitors metabolism urine therapeutic use MeSH
- Sodium-Glucose Transporter 2 metabolism urine therapeutic use MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Humans MeSH
- MeSH
- Albuminuria complications MeSH
- Renal Insufficiency, Chronic epidemiology etiology MeSH
- Diabetes Mellitus, Type 2 * complications blood MeSH
- Diabetic Retinopathy epidemiology etiology MeSH
- Diabetic Angiopathies * epidemiology MeSH
- Diabetic Nephropathies * epidemiology MeSH
- Glycated Hemoglobin * analysis diagnostic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Prevalence MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Aged MeSH
- Publication type
- Comment MeSH
- Overall MeSH
- Geographicals
- Italy MeSH
- MeSH
- Diabetes Mellitus diagnosis MeSH
- Glycated Hemoglobin analysis diagnostic use MeSH
- Coronary Angiography MeSH
- Blood Glucose analysis physiology MeSH
- Humans MeSH
- Mass Screening methods MeSH
- Check Tag
- Humans MeSH
- Publication type
- Comment MeSH
Diabetes mellitus 2. typu je heterogenní onemocnění, stávajícími prostředky se nedaří u všech pacientů dosáhnout cílových hodnot kompenzace. Jsou proto vyvíjeny nové variace již osvědčených farmak (inzulín degludec, agonista receptoru pro GLP 1 lixisenatid), hledány nové cesty využití již známých terapeutických cílů (chimerické peptidy, nepeptidové aktivátory inzulínového receptoru či receptoru pro GLP 1, glitazary). Jsou také objevovány zcela nové možnosti pro terapii hyperglykémie (aktivátory glukokinázy, inhibitory SGLT 2, inhibitory 11ß-hydroxysteroidní dehydrogenázy typu 1). V brzké době se rozšíří možnosti farmakoterapie diabetu 2. typu.
Type 2 diabetes mellitus is a heterogeneous disease and using the current therapeutic means, it is not always possible to achieve the target levels of compensation. For that reason, new variations of the already established preparations are being developed (insulin degludec, lixisenatide – a GLP1 receptor agonist) and new ways of utilising already known therapeutic goals are being researched (chimeric peptids, non-peptid activators of insulin receptors or GLP1 receptors, glitazars). There are also whole new options being discovered for hyperglycaemia treatment (glucokinase activators, SGLT-2 inhibitors, inhibitors of type 1 11ß-hydroxysteroid dehydrogenase). It is thus possible to expect new options in pharmacotherapy of type 2 diabetes in the near future.
- Keywords
- inzulín degludec, inzulín degludec, lixisenatid, aleglitazar, dapagliflozin,
- MeSH
- 11-beta-Hydroxysteroid Dehydrogenases antagonists & inhibitors MeSH
- Diabetes Mellitus, Type 2 therapy MeSH
- Financing, Organized MeSH
- Sodium-Glucose Transporter 2 Inhibitors MeSH
- Glucagon-Like Peptide 1 agonists MeSH
- Glucokinase metabolism therapeutic use MeSH
- Insulin Glargine MeSH
- Insulin analogs & derivatives physiology therapeutic use MeSH
- Clinical Trials as Topic MeSH
- Humans MeSH
- PPAR alpha agonists MeSH
- PPAR gamma agonists MeSH
- Receptors, Cell Surface MeSH
- Sodium-Glucose Transporter 2 MeSH
- Check Tag
- Humans MeSH
55letý pacient s diabetem 1. typu s potvrzenými mikroangiopatickými komplikacemi yl hospitalizován pro vertigo a pomalu progredující kvadruparézu. Vstupní laboratorní vyšetření naznačila podezření na perniciózní anemii, která byla potvrzena nálezem chronické atrofické gastritidy při endoskopickém vyšetření, které navíc odhalilo dva polypózní útvary, z nichž jeden byl tvořen karcinoidem. Klinické projevy tohoto neuroendokrinního tumoru nejsou časté, ale jeho incidence v posledních dekádách stoupá a je spjata s parakrinní dysregulací v žaludeční sliznici při atrofické gastritidě. Po úspěšné léčbě karcinoidu pacient vyžaduje i nadále dispenzární péči pro riziko vzniku žaludečního karcinomu, který se vyvíjí až v 6 % případů. Předložená kazuistika zdůrazňuje pečlivé posouzení projevů tzv. sdružené autoimunity, v jejímž terénu se na podkladě autoimunitní chronické atrofické gastritidy vyvinula nejen perniciózní anemie, ale i karcinoid.
A 55 years old patient with type 1 diabetes mellitus and proved microangiopatic complications was hospitalized for vertigo and a slowly progressive quadruparesis. Initial laboratory tests suggested the pernicious anemia, which was proved by a diagnosis of atrophic gastritis by gastroendoscopy that also revealed two polypose formations, one of them was formed by the carcinoid. Clinical symptoms of this neuroendocrine tumor are not frequent, but its incidence has increased in last decades and it is associated with a paracrinne deregulation in a gastric mucosa in atrophic gastritis. Following a successful treatment of the carcinoid the patient needs a further follow-up care due to a risk of a gastric cancer that develops in up to 6 % cases. The presented case report highlights a careful assessment of symptoms of so called associated autoimmunity, which was the underlying cause of the autoimmune chronic atrophic gastritis inducing not only the pernicious anemia but also the carcinoid.
- MeSH
- Autoimmunity physiology MeSH
- Diabetes Mellitus, Type 1 * immunology complications MeSH
- Diagnostic Techniques and Procedures MeSH
- Diagnosis, Differential MeSH
- Gastritis, Atrophic diagnosis etiology pathology MeSH
- Carcinoid Tumor * diagnosis etiology therapy MeSH
- Diabetes Complications MeSH
- Middle Aged MeSH
- Humans MeSH
- Anemia, Pernicious pathology therapy MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Case Reports MeSH
- MeSH
- Rats MeSH
- Melatonin therapeutic use MeSH
- Tryptamines therapeutic use MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
